Expiration date: 07/2026
Dosage form
ointment light yellow color with a characteristic odor.
Composition
Composition 100 g of ointment:
Active substance: chondroitin sulfate sodium, calculated on the dry substance at 5.0 g.
Auxiliary substances: dimethyl sulfoxide - 10.0 g; vaseline 50.0 g; lanolin 15.0 g; distilled water - up to 100,0
Pharmacological action
Artrafic stimulates regeneration (recovery) processes and normalizes metabolism in the articular cartilage, has analgesic and anti-inflammatory effect, slows the progression of osteoarthritis and degenerative disc disease. Artrafic contains a natural component of chondroitin sulphate (a mucopolysaccharide of high molecular weight), obtained from the tissues of cattle. Chondroitin sulfate improves calcium and phosphorus metabolism in the cartilage tissue, accelerates its repair, hinders the process of degeneration (destruction) of cartilage; prevents the collapse of connective tissue; inhibits the enzymes that cause cartilage damage, stimulates the synthesis of glycosaminoglycans, contributes to the regeneration (restoration) of the joint capsule and cartilage surfaces of the joints, increases the production of synovial fluid. This leads to a reduction of pain and increase of mobility of the affected joints.
Pharmacokinetics
In accordance with the data obtained in experimental studies on mice using radiochango ZN-chondroitin sulfate, an indicator of the absorbability of chondroitin sulfate is 14%. The dimethyl sulfoxide is included in the ointment, promotes better penetration of chondroitin sulfate through the cell membrane into tissues. Chondroitin sulfate after application of the ointment on the skin enters into the joint to achieve maximum concentration after 30 minutes and the subsequent two-phase excretion of the drug from cartilage. The completion of the fast phase of elimination occurs in 1 hour
after application. The retention time of the drug in the joint is 5 hours.
Side effects
Allergic reactions.
Features sale
Without prescription
Special conditions
Avoid contact of the drug Artrafic mucous membranes and open wounds.
Effect on driving and operating machinery does Not affect the ability of the patient to engage in potentially hazardous activities, require increased attention and rapid mental and motor reactions.
Testimony
Treatment and prevention of degenerative disc disease, osteoarthritis peripheral joints and spine.
Contraindications
Hypersensitivity to the drug. Violation of the integrity of the skin in areas proposed application of the drug.
WITH CAUTION
Pregnancy, breastfeeding, children up to age 18 years (effectiveness and safety have not been established).
Drug interactions
Cases interaction or incompatibility with other drugs has not been described.
